American Century Companies Inc. Has $1.58 Million Holdings in Delek US Holdings, Inc. (DK)

American Century Companies Inc. reduced its position in shares of Delek US Holdings, Inc. (NYSE:DK) by 4.1% in the first quarter, HoldingsChannel reports. The firm owned 38,843 shares of the oil and gas company’s stock after selling 1,680 shares during the quarter. American Century Companies Inc.’s holdings in Delek US were worth $1,581,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. BlackRock Inc. grew its stake in shares of Delek US by 3.1% in the fourth quarter. BlackRock Inc. now owns 5,148,200 shares of the oil and gas company’s stock worth $179,880,000 after acquiring an additional 154,903 shares during the period. Goldman Sachs Group Inc. grew its stake in shares of Delek US by 73.9% in the fourth quarter. Goldman Sachs Group Inc. now owns 2,963,259 shares of the oil and gas company’s stock worth $103,536,000 after acquiring an additional 1,258,853 shares during the period. TIAA CREF Investment Management LLC grew its stake in shares of Delek US by 0.4% in the fourth quarter. TIAA CREF Investment Management LLC now owns 1,893,620 shares of the oil and gas company’s stock worth $66,163,000 after acquiring an additional 7,330 shares during the period. Bank of New York Mellon Corp grew its stake in shares of Delek US by 21.4% in the fourth quarter. Bank of New York Mellon Corp now owns 1,396,175 shares of the oil and gas company’s stock worth $48,782,000 after acquiring an additional 246,572 shares during the period. Finally, Renaissance Technologies LLC bought a new stake in shares of Delek US in the fourth quarter worth approximately $40,703,000. Institutional investors and hedge funds own 96.29% of the company’s stock.

Get Delek US alerts:

A number of analysts have recently commented on the stock. ValuEngine lowered shares of Delek US from a “buy” rating to a “hold” rating in a research note on Thursday, May 24th. JPMorgan Chase & Co. upgraded shares of Delek US from a “neutral” rating to an “overweight” rating and set a $44.00 price target for the company in a research note on Monday, May 14th. Wells Fargo & Co lifted their price target on shares of Delek US from $49.00 to $60.00 and gave the stock an “outperform” rating in a research note on Wednesday, May 9th. Bank of America set a $50.00 price target on shares of Delek US and gave the stock a “hold” rating in a research note on Tuesday, May 8th. Finally, Zacks Investment Research upgraded shares of Delek US from a “hold” rating to a “buy” rating and set a $52.00 price target for the company in a research note on Wednesday, April 18th. Five investment analysts have rated the stock with a hold rating, twelve have issued a buy rating and two have issued a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $44.79.

Shares of Delek US opened at $52.08 on Tuesday, Marketbeat reports. The company has a current ratio of 1.34, a quick ratio of 0.89 and a debt-to-equity ratio of 0.99. Delek US Holdings, Inc. has a 1-year low of $20.65 and a 1-year high of $54.28. The company has a market cap of $4.38 billion, a price-to-earnings ratio of 41.33, a PEG ratio of 1.25 and a beta of 1.43.

Delek US (NYSE:DK) last issued its quarterly earnings results on Monday, May 7th. The oil and gas company reported $0.33 earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.44. Delek US had a net margin of 2.89% and a return on equity of 6.51%. The business had revenue of $2.35 billion for the quarter, compared to the consensus estimate of $2.10 billion. equities research analysts predict that Delek US Holdings, Inc. will post 4.18 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Monday, June 4th. Shareholders of record on Monday, May 21st will be issued a dividend of $0.25 per share. The ex-dividend date of this dividend is Friday, May 18th. This represents a $1.00 annualized dividend and a yield of 1.92%. This is an increase from Delek US’s previous quarterly dividend of $0.20. Delek US’s payout ratio is currently 79.37%.

Delek US declared that its Board of Directors has authorized a stock repurchase plan on Monday, February 26th that permits the company to buyback $150.00 million in outstanding shares. This buyback authorization permits the oil and gas company to reacquire shares of its stock through open market purchases. Shares buyback plans are typically a sign that the company’s board of directors believes its shares are undervalued.

In other Delek US news, CFO Kevin L. Kremke sold 3,400 shares of Delek US stock in a transaction that occurred on Tuesday, March 13th. The shares were sold at an average price of $37.01, for a total transaction of $125,834.00. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Avigal Soreq sold 3,091 shares of Delek US stock in a transaction that occurred on Wednesday, March 7th. The shares were sold at an average price of $36.00, for a total transaction of $111,276.00. The disclosure for this sale can be found here. Insiders have sold 243,591 shares of company stock worth $9,500,435 in the last ninety days. Insiders own 1.40% of the company’s stock.

Delek US Company Profile

Delek US Holdings, Inc engages in the integrated downstream energy business in the United States. The company's Refining segment processes crude oil and other purchased feedstocks for the manufacture of various grades of gasoline, diesel fuel, aviation fuel, asphalt, and other petroleum-based products that are distributed through owned and third-party product terminals.

Want to see what other hedge funds are holding DK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Delek US Holdings, Inc. (NYSE:DK).

The three biggest risks to global investors

Investors should watch out for three big risks as they enter into the second half of the year.

On CNNMoney's "Markets Now" Wednesday, analyst Darius Dale warned about the strengthening dollar, wage growth and a peaking global economy.

"There's a lot of negative signals out there that seem to suggest that we're not going to be able to surpass this historically high level of operating margins," Dale, a senior macro analyst with investment research firm Hedgeye Risk Management, told CNNMoney anchor Maggie Lake.

Dale predicts that the pace of economic growth and inflation will slow this year, but he doesn't think a recession is coming soon.

Dale said that investors should avoid consumer staples, the industrial sector, and even some technology companies.

Investors who bet on tech companies that rely on economic strength, like semiconductors, for example, could be making "a huge mistake."

Dale also cast doubt on the Trump administration's ability to hit its 3% growth target because companies have been spending savings from their new lower tax rate on stock buybacks, rather than investing in new facilities or research.

CNNMoney's "Markets Now" streams live from the New York Stock Exchange every Wednesday at 12:45 p.m. ET. Hosted by Lake and CNNMoney editor-at-large Richard Quest, the 15-minute long program features incisive commentary from experts. Recent guests include former Chrysler and Home Depo (HD)CEO Bob Nardelli and Bitcoin bull Mike Novogratz.

You can watch "Markets Now" at CNNMoney.com/MarketsNow from your desk or on your phone or tablet. If you can't catch the show live, check out highlights online and through the Markets Now newsletter, delivered to your inbox every afternoon.

day trading penny stocks

tags:PANW,NWL,SORL,ITT,EQS,

CEO of Fs Investment Corp (NYSE:FSIC) Michael C. Forman bought 33,800 shares of FSIC on 02/09/2018 at an average price of $7.33 a share. The total cost of this purchase was $247,754.

FS Investment Corporation is an investment company. Its business objective is to achieve long-term capital appreciation and income by investing in a diverse range of sectors such as capital goods, apparels and financial services. FS Investment Corp has a market cap of $1.78 billion; its shares were traded at around $7.25 with a P/E ratio of 8.05 and P/S ratio of 5.23. The dividend yield of FS Investment Corp stocks is 11.85%.

CEO Recent Trades:

CEO Michael C. Forman bought 33,800 shares of FSIC stock on 02/09/2018 at the average price of $7.33. The price of the stock has decreased by 1.09% since.CEO Michael C. Forman bought 33,500 shares of FSIC stock on 02/07/2018 at the average price of $7.45. The price of the stock has decreased by 2.68% since.CEO Michael C. Forman bought 17,158 shares of FSIC stock on 02/05/2018 at the average price of $7.44. The price of the stock has decreased by 2.55% since.

Directors and Officers Recent Trades:

day trading penny stocks: Palo Alto Networks, Inc.(PANW)

Advisors' Opinion:

• [By Motley Fool Staff]

  Developing brands like Tesla face a different challenge.�These are companies valued largely on potential for sales, not profit. Tesla, for example, has a huge backlog of Model 3 orders to fill, but it has yet to show it can operate profitably.�Palo Alto Networks�(NYSE: PANW), a cybersecurity company, is in a similar position, boasting a significant customer base but still not showing consistent profits.�In most cases, these brands lose money -- sometimes a lot of it -- as they build out capacity and develop a market for their product. Emerging companies generally have more upside (at least at first), but they come with significant risk.�

• [By Harsh Chauhan]

  Pure-play cybersecurity specialist Palo Alto Networks (NYSE:PANW) has done well to carve a strong position in this market, recording impressive revenue growth over the years.

• [By ]

  Palo Alto Networks (NYSE: PANW) shares jumped 7% after hours yesterday when the company topped earnings expectations and issued strong guidance.

  We��ve maintained a PANW in the portfolio since June �� and we suggested adding to your position back on Feb. 14th after the stock tagged our preliminary target of $160. Now that the stock is approaching $180 after hours, it has the momentum it needs to make a run at its 2015 all-time highs near $200.

• [By Steve Symington]

  As for individual stocks, a spinoff at Hewlett-Packard Enterprise (NYSE:HPE) drove a deceiving downward move today, and earnings news from Palo Alto Networks (NYSE:PANW) sent shares of the next-gen security specialist higher.

• [By Nicholas Rossolillo]

  Fueled by increasing need for cybersecurity and a run of better-than-expected financial results, shares of Palo Alto Networks (NYSE:PANW) have rallied 70% in the last year. Cybersecurity is a young but fast-growing industry, and Palo Alto Networks is one of the leading providers of the service. That could equate to further upside for owners of this stock.

• [By Chris Lange]

  Palo Alto Networks Inc.’s (NYSE: PANW) fiscal second-quarter report is scheduled for Monday. The consensus estimates are calling for $0.79 in earnings per share (EPS) on $524.82 million in revenue. The shares traded on Friday��s close at $165.54. The consensus price target is $173.27, and the 52-week trading range is $107.31 to $167.73.

day trading penny stocks: Newell Rubbermaid Inc.(NWL)

Advisors' Opinion:

• [By ]

  TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer weighs in on Tuesday's trending topics including Goldman Sachs (GS) , JPMorgan Chase (JPM) , Newell Brands (NWL) and Domino's Pizza (DPZ) .

• [By ]

  Activist investor-pressured Mr. Coffee maker Newell Brands (NWL) plans to announce the terms of the first wave of divestitures contemplated in an initial $6 billion asset sale plan in the coming weeks, according to Wells Fargo analysts.

• [By ]

  Not every battle is worth fighting, Cramer told viewers. That's especially true if you own shares of Newell Brands (NWL) , which is embroiled in a bitter proxy fight between activists Starboard Capital and Carl Icahn.

day trading penny stocks: SORL Auto Parts Inc.(SORL)

Advisors' Opinion:

• [By Lisa Levin] Gainers Euro Tech Holdings Company Limited (NASDAQ: CLWT) shares climbed 70.3 percent to $5.45 after reporting 2017 year-end results. MEDIGUS Ltd/S ADR (NASDAQ: MDGS) surged 39.8 percent to $1.58 in reaction to its Monday announcement of a distribution agreement. The medical device company said it reached an agreement to distribute its minimally invasive medical devices in Turkey, Azerbaijan and Georgia. Arcadia Biosciences, Inc. (NASDAQ: RKDA) gained 25.6 percent to $11.50. Arcadia Biosciences reported that Albert D. Bolles, Ph.D. has joined its board of directors. Aytu Bioscience Inc (NASDAQ: AYTU) shares jumped 21.8 percent to $0.4798 after the company late Monday reported lighter-than-expected Q1 loss. Hollysys Automation Technologies Ltd. (NASDAQ: HOLI) shares gained 21.1 percent to $26.77 following Q3 results. Pfenex Inc. (NYSE: PFNX) rose 16.8 percent to $7.1271 after the company announced the positive top-line PF708 study results in Osteoporosis patients that showed no imbalances in severity or incidence of adverse events. MEI Pharma, Inc. (NASDAQ: MEIP) rose 13.8 percent to $2.88. Red Violet, Inc. (NASDAQ: RDVT) jumped 13.1 percent to $6.41 after reporting Q1 results. SORL Auto Parts, Inc. (NASDAQ: SORL) shares gained 12 percent to $5.87 after reporting upbeat Q1 results. Bovie Medical Corporation (NYSE: BVX) gained 8.4 percent to $3.96 after reporting a first-quarter sales beat. Rosehill Resources Inc. (NASDAQ: ROSE) surged 8.4 percent to $7.90 after announcing Q1 results. LiqTech International, Inc. (NASDAQ: LIQT) rose 8.1 percent to $0.5171 following Q1 results. ProPhase Labs, Inc. (NASDAQ: PRPH) rose 7.7 percent to $5.6103 following Q1 results. Nine Energy Service, Inc. (NYSE: NINE) shares climbed 7.4 percent to $35.90. Xenon Pharmaceuticals Inc. (NASDAQ: XENE) rose 6.7 percent to $6.40 after the company presented XEN901 Phase 1 clinical update and XEN1101 TMS pharmacodynamic Phase 1 data. MYnd
• [By Lisa Levin] Gainers Euro Tech Holdings Company Limited (NASDAQ: CLWT) shares rose 14.1 percent to $3.65 in the pre-market trading session after reporting 2017 year-end results. LightPath Technologies, Inc. (NASDAQ: LPTH) rose 13.3 percent to $2.43 in pre-market trading after reporting a third-quarter earnings beat. MYnd Analytics, Inc. (NASDAQ: MYND) rose 10.5 percent to $3.49 in pre-market trading. MYnd Analytics reported a Q2 net loss of $2.7 million on revenue of $459,900. SORL Auto Parts, Inc. (NASDAQ: SORL) shares rose 8.4 percent to $5.68 in pre-market trading after reporting upbeat Q1 results. Famous Dave's of America, Inc. (NASDAQ: DAVE) shares rose 7.7 percent to $8.40 in pre-market trading after the company reported upbeat earnings for its first quarter on Monday. Xenon Pharmaceuticals Inc. (NASDAQ: XENE) rose 7.5 percent to $6.45 in pre-market trading after the company presented XEN901 Phase 1 clinical update and XEN1101 TMS pharmacodynamic Phase 1 data. Mimecast Ltd (NASDAQ: MIME) rose 6.5 percent to $43.50 in pre-market trading following a first-quarter sales beat. Boxlight Corporation (NASDAQ: BOXL) rose 6 percent to $12.50 in pre-market trading after surging 77.44 percent on Monday. Intellia Therapeutics, Inc. (NASDAQ: NTLA) shares rose 6 percent to $26.05 in pre-market trading after climbing 3.58 percent on Monday. PPDAI Group Inc. (NASDAQ: PPDF) rose 4.7 percent to $7.20 in pre-market trading following Q1 results. Xunlei Limited (NASDAQ: XNET) rose 4.1 percent to $13.88 in pre-market trading after gaining 2.54 percent on Monday. Valeant Pharmaceuticals International, Inc. (NYSE: VRX) shares rose 4.5 percent to $21.73 in pre-market trading. Mizuho upgraded Valeant from Neutral to Buy. Bovie Medical Corporation (NYSE: BVX) rose 4.1 percent to $3.80 in pre-market trading after reporting a first-quarter sales beat. Myomo, Inc. (NYSE: MYO) rose 3.4 percent to $4.00 in pre-market trading after jumping 23.25 percent o
• [By Lisa Levin]

  SORL Auto Parts, Inc. (NASDAQ: SORL) is expected to report quarterly earnings at $0.19 per share on revenue of $86.96 million.

  Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) is projected to report quarterly loss at $0.39 per share.

• [By Lisa Levin]

  Shares of SORL Auto Parts, Inc. (NASDAQ: SORL) got a boost, shooting up 13 percent to $5.90 after reporting upbeat Q1 results.

  Hollysys Automation Technologies Ltd. (NASDAQ: HOLI) shares were also up, gaining 24 percent to $27.3947 following Q3 results.

• [By Lisa Levin] Gainers Red Violet, Inc. (NASDAQ: RDVT) rose 75.31 percent to close at $9.94 after reporting Q1 results. Euro Tech Holdings Company Limited (NASDAQ: CLWT) shares jumped 40.62 percent to close at $4.50 on Tuesday after reporting 2017 year-end results. MEI Pharma, Inc. (NASDAQ: MEIP) gained 34.39 percent to close at $3.40. MEDIGUS Ltd/S ADR (NASDAQ: MDGS) gained 32.74 percent to close at $1.50 in reaction to its Monday announcement of a distribution agreement. The medical device company said it reached an agreement to distribute its minimally invasive medical devices in Turkey, Azerbaijan and Georgia. Pfenex Inc. (NYSE: PFNX) surged 31.15 percent to close at $8.00 after the company announced the positive top-line PF708 study results in Osteoporosis patients that showed no imbalances in severity or incidence of adverse events. Arcadia Biosciences, Inc. (NASDAQ: RKDA) rose 21.07 percent to close at $11.09. Arcadia Biosciences reported that Albert D. Bolles, Ph.D. has joined its board of directors. Genprex, Inc. (NASDAQ: GNPX) rose 20.23 percent to close at $10.58. Turtle Beach Corporation (NASDAQ: HEAR) shares gained 17.62 percent to close at $17.82. Aptevo Therapeutics Inc. (NASDAQ: APVO) rose 17.1 percent to close at $5.82. Phoenix New Media Limited (NYSE: FENG) shares jumped 16.23 percent to close at $4.87 following Q1 earnings. Stein Mart, Inc. (NASDAQ: SMRT) rose 16.04 percent to close at $3.69. PPDAI Group Inc. (NASDAQ: PPDF) climbed 15.99 percent to close at $7.98 following Q1 results. Tyme Technologies, Inc. (NASDAQ: TYME) rose 15.93 percent to close at $3.42. LiqTech International, Inc. (NASDAQ: LIQT) gained 15.59 percent to close at $0.5532 following Q1 results. Sophiris Bio, Inc. (NASDAQ: SPHS) gained 13.92 percent to close at $3.52 on Tuesday following Q1 results. Euroseas Ltd. (NASDAQ: ESEA) jumped 13.4 percent to close at $2.37. Iteris, Inc. (NASDAQ: ITI) shares surged 13.05 percent to close

day trading penny stocks: ITT Corporation(ITT)

Advisors' Opinion:

• [By Lisa Levin] Companies Reporting Before The Bell Celgene Corporation (NASDAQ: CELG) is projected to report quarterly earnings at $1.96 per share on revenue of $3.46 billion. Aon plc (NYSE: AON) is expected to report quarterly earnings at $2.8 per share on revenue of $2.93 billion. American Axle & Manufacturing Holdings, Inc. (NYSE: AXL) is estimated to report quarterly earnings at $0.81 per share on revenue of $1.75 billion. Alibaba Group Holding Limited (NYSE: BABA) is expected to report quarterly earnings at $0.88 per share on revenue of $9.27 billion. LifePoint Health, Inc. (NASDAQ: LPNT) is projected to report quarterly earnings at $1.13 per share on revenue of $1.62 billion. V.F. Corporation (NYSE: VFC) is estimated to report quarterly earnings at $0.65 per share on revenue of $2.90 billion. Newell Brands Inc. (NYSE: NWL) is expected to report quarterly earnings at $0.26 per share on revenue of $3.05 billion. Titan International, Inc. (NYSE: TWI) is projected to report quarterly earnings at $0.04 per share on revenue of $407.27 million. Boise Cascade Company (NYSE: BCC) is expected to report quarterly earnings at $0.45 per share on revenue of $1.09 billion. Cheniere Energy, Inc. (NYSE: LNG) is estimated to report quarterly earnings at $0.39 per share on revenue of $1.59 billion. Cboe Global Markets, Inc. (NASDAQ: CBOE) is projected to report quarterly earnings at $1.24 per share on revenue of $308.05 million. ITT Inc. (NYSE: ITT) is estimated to report quarterly earnings at $0.73 per share on revenue of $683.96 million. Fred's, Inc. (NASDAQ: FRED) is expected to report quarterly loss at $0.19 per share on revenue of $551.00 million. Virtu Financial, Inc. (NASDAQ: VIRT) is projected to report quarterly earnings at $0.52 per share on revenue of $288.31 million. Cheniere Energy Partners, L.P. (NYSE: CQP) is expected to report quarterly earnings at $0.57 per share on revenue of $1.38 billion. Genesis Energy, L.P
• [By Ethan Ryder]

  Intelligent Trading Foundation (CURRENCY:ITT) traded 1.1% higher against the US dollar during the 1 day period ending at 8:00 AM ET on April 18th. In the last week, Intelligent Trading Foundation has traded up 19.5% against the US dollar. One Intelligent Trading Foundation token can currently be purchased for about $0.0764 or 0.00000942 BTC on cryptocurrency exchanges including COSS, EtherDelta (ForkDelta), IDEX and Mercatox. Intelligent Trading Foundation has a total market cap of $749,032.00 and approximately $863.00 worth of Intelligent Trading Foundation was traded on exchanges in the last 24 hours.

day trading penny stocks: Equus Total Return, Inc.(EQS)

Advisors' Opinion:

• [By Anders Melin]

  Taking that a step further, you can run searches on the Equity Screening (EQS) function using the new pay metrics or data on say-on-pay, which refers to shareholders’ right to vote on management remuneration. To see Russell 1000 companies with the lowest support on pay, for example, go to {EQS <GO>}. In the Add Criteria field, enter RIY and click on the Russell 1000 Index match. Next, enter Say on Pay, click on the Say on Pay Support Level item, and press <GO>. Click on the See Results | WATC button for a list of companies in the benchmark that you can sort by the percentage of shareholders supporting management on pay.

Zacks: Analysts Anticipate bluebird bio (BLUE) to Announce -$2.27 EPS

Brokerages expect bluebird bio (NASDAQ:BLUE) to announce earnings of ($2.27) per share for the current fiscal quarter, Zacks reports. Six analysts have made estimates for bluebird bio’s earnings. The highest EPS estimate is ($0.84) and the lowest is ($2.55). bluebird bio reported earnings of ($1.73) per share in the same quarter last year, which would suggest a negative year over year growth rate of 31.2%. The firm is expected to announce its next quarterly earnings report on Wednesday, August 1st.

According to Zacks, analysts expect that bluebird bio will report full-year earnings of ($9.33) per share for the current fiscal year, with EPS estimates ranging from ($10.89) to ($4.74). For the next fiscal year, analysts forecast that the company will report earnings of ($9.23) per share, with EPS estimates ranging from ($12.17) to ($3.81). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research firms that follow bluebird bio.

Get bluebird bio alerts:

bluebird bio (NASDAQ:BLUE) last posted its quarterly earnings results on Monday, May 7th. The biotechnology company reported ($2.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.01) by ($0.30). The company had revenue of $15.96 million during the quarter, compared to analyst estimates of $5.85 million. bluebird bio had a negative net margin of 857.55% and a negative return on equity of 27.61%. The company’s revenue was up 133.7% on a year-over-year basis. During the same period in the prior year, the company earned ($1.68) earnings per share.

Several analysts recently issued reports on the stock. Maxim Group reaffirmed a “hold” rating and issued a $200.00 price target on shares of bluebird bio in a report on Thursday, February 22nd. Canaccord Genuity reaffirmed a “buy” rating and issued a $250.00 price target on shares of bluebird bio in a report on Tuesday, March 13th. Leerink Swann cut shares of bluebird bio from an “outperform” rating to a “market perform” rating and upped their price target for the company from $162.00 to $194.00 in a report on Thursday, January 25th. SunTrust Banks upped their price target on shares of bluebird bio to $232.00 and gave the company a “buy” rating in a report on Thursday, April 19th. Finally, BidaskClub raised shares of bluebird bio from a “buy” rating to a “strong-buy” rating in a report on Friday, January 26th. Four investment analysts have rated the stock with a sell rating, nine have given a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company. The company has a consensus rating of “Hold” and a consensus target price of $195.80.

BLUE traded down $5.60 during trading on Friday, hitting $183.70. The company had a trading volume of 665,896 shares, compared to its average volume of 778,666. The stock has a market capitalization of $8.94 billion, a PE ratio of -23.83 and a beta of 2.17. bluebird bio has a 1-year low of $74.45 and a 1-year high of $236.17.

In other bluebird bio news, insider David Davidson sold 13,000 shares of the business’s stock in a transaction on Wednesday, May 2nd. The shares were sold at an average price of $177.52, for a total transaction of $2,307,760.00. Following the completion of the sale, the insider now owns 37,905 shares in the company, valued at $6,728,895.60. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Mark Vachon sold 6,000 shares of the business’s stock in a transaction on Thursday, March 15th. The shares were sold at an average price of $214.38, for a total transaction of $1,286,280.00. Following the sale, the director now owns 7,000 shares of the company’s stock, valued at approximately $1,500,660. The disclosure for this sale can be found here. In the last quarter, insiders have sold 46,250 shares of company stock valued at $8,269,990. 3.90% of the stock is owned by insiders.

Several institutional investors have recently added to or reduced their stakes in the company. Hanseatic Management Services Inc. grew its position in shares of bluebird bio by 14.6% during the fourth quarter. Hanseatic Management Services Inc. now owns 2,334 shares of the biotechnology company’s stock worth $416,000 after acquiring an additional 298 shares during the last quarter. Commonwealth Equity Services LLC grew its position in shares of bluebird bio by 24.7% during the first quarter. Commonwealth Equity Services LLC now owns 1,936 shares of the biotechnology company’s stock worth $330,000 after acquiring an additional 383 shares during the last quarter. Winfield Associates Inc. grew its position in shares of bluebird bio by 12.4% during the first quarter. Winfield Associates Inc. now owns 3,620 shares of the biotechnology company’s stock worth $618,000 after acquiring an additional 400 shares during the last quarter. Macquarie Group Ltd. grew its position in shares of bluebird bio by 2.3% during the fourth quarter. Macquarie Group Ltd. now owns 19,102 shares of the biotechnology company’s stock worth $3,402,000 after acquiring an additional 438 shares during the last quarter. Finally, Kazazian Asset Management LLC grew its position in shares of bluebird bio by 11.6% during the fourth quarter. Kazazian Asset Management LLC now owns 4,555 shares of the biotechnology company’s stock worth $811,000 after acquiring an additional 472 shares during the last quarter.

bluebird bio Company Profile

bluebird bio, Inc, a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates include Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in various clinical studies for the treatment of transfusion- transfusion-dependent �-thalassemia and severe sickle cell disease.

Get a free copy of the Zacks research report on bluebird bio (BLUE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com